Q-omics provides the consensus-scored C11orf97 profile across patient tissues and cancer cell-line models. C11orf97 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C11orf97 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, C11orf97 RNA expression shows 9,886 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and LUAD as cancer lineages where C11orf97 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf97 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf97 survival associations across molecular data types. C11orf97 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf97 RNA expression–survival associations across cancer types. High C11orf97 expression shows unfavorable associations in KICH and MESO, but favorable associations in KIRP, KIRC, LAML and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C11orf97 RNA expression.
This table summarizes C11orf97 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for C11orf97. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf97 shows lower tumor expression in LUAD, LUSC, KICH, THCA, KIRP and UCEC. The LUAD box plot shows higher C11orf97 RNA expression in normal versus tumor tissue (log2 FC = −2.272, t-test p < 0.001).
This table shows molecular features associated with C11orf97 in patient tissues and cancer cell lines. In patient samples, C11orf97 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf97 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
